Amneal Pharmaceuticals, Inc. SEC filings AMRX
Amneal Pharmaceuticals, Inc. has 694 filings in SEC EDGAR's recent list, going back to Nov 21, 2017. Its latest annual report, Form 10-K, was filed on Feb 27, 2026 for the period ended Dec 31, 2025. The latest quarterly report (Form 10-Q) was filed on Aug 6, 2026, covering the quarter ended Jun 30, 2026. The most recent current report (Form 8-K) was filed on Nov 3, 2026 (results of operations, regulation fd disclosure). The company's fiscal year ends on December 31.
| Form | Description | Filed | Period |
|---|---|---|---|
| DEFA14A | Additional proxy material | Jul 30, 2026 | — |
| DEFM14A | Filing | Jun 29, 2026 | — |
| PREM14A | Filing | Jun 18, 2026 | Jun 18, 2026 |
| DEFA14A | Additional proxy material | Apr 23, 2026 | — |
| DEFA14A | Additional proxy material | Apr 22, 2026 | — |
| DEFA14A | Additional proxy material | Apr 22, 2026 | — |
| DEFA14A | Additional proxy material | Apr 22, 2026 | — |
| DEFA14A | Additional proxy material | Apr 22, 2026 | — |
| DEFA14A | Additional proxy material | Apr 22, 2026 | — |
| DEFA14A | Additional proxy material | Apr 22, 2026 | — |
| DEFA14A | Additional proxy material | Mar 25, 2026 | — |
| DEF 14A | Proxy statement | Mar 25, 2026 | May 6, 2026 |
| DEFA14A | Additional proxy material | Mar 25, 2025 | — |
| DEF 14A | Proxy statement | Mar 25, 2025 | May 6, 2025 |
| DEFA14A | Additional proxy material | Mar 22, 2024 | — |
| DEF 14A | Proxy statement | Mar 22, 2024 | May 2, 2024 |
| DEFA14A | Additional proxy material | Mar 24, 2023 | — |
| DEF 14A | Proxy statement | Mar 24, 2023 | — |
| DEFA14A | Additional proxy material | Mar 25, 2022 | — |
| DEF 14A | Proxy statement | Mar 25, 2022 | May 9, 2022 |
| DEFA14A | Additional proxy material | Mar 24, 2021 | — |
| DEF 14A | Proxy statement | Mar 24, 2021 | May 5, 2021 |
| PRE 14A | Preliminary proxy statement | Mar 8, 2021 | May 5, 2021 |
| DEFA14A | Additional proxy material | Apr 15, 2020 | — |
| DEFA14A | Additional proxy material | Mar 23, 2020 | — |
| DEF 14A | Proxy statement | Mar 23, 2020 | May 5, 2020 |
| DEF 14C | Information statement | Oct 21, 2019 | Oct 23, 2019 |
| PRE 14C | Preliminary information statement | Oct 11, 2019 | Oct 11, 2019 |
| DEFA14A | Additional proxy material | Mar 22, 2019 | — |
| DEF 14A | Proxy statement | Mar 22, 2019 | May 6, 2019 |
Showing 30 filings. Main filings leave out insider and ownership forms such as Form 4; choose a type above to see them. Each form opens on SEC.gov. Older filings are on SEC EDGAR.
New to this? Read What Are SEC Filings? 10-K, 10-Q, 8-K and Other Forms Explained.
Company profile
- Industry
- Pharmaceutical Preparations (SIC 2834)
- Listed as
- AMRX (Nasdaq)
- Fiscal year ends
- December 31
- SEC filer status
- Large accelerated filer
- SEC CIK
- 1723128
- Former names
- Atlas Holdings, Inc. (until Apr 13, 2018)
Other Pharmaceutical Preparations companies
- ELI LILLY & Co LLY
- Johnson & Johnson JNJ
- AbbVie Inc. ABBV
- Merck & Co., Inc. MRK
- Novartis AG NVS
- Astrazeneca PLC AZN
- Abbott Laboratories ABT
- Novo Nordisk A S NVO
Source: SEC EDGAR filings. This is company-reported data, not investment advice.